Literature DB >> 19351926

Does treatment intensity matter in superficial bladder cancer? Consensus, clinical practice, and confounding.

Gary H Lyman, Nicole M Kuderer, Stephen J Freedland.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19351926      PMCID： PMC4415052          DOI： 10.1093/jnci/djp060

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  19 in total

1.  Hospital volume and surgical mortality in the United States.

Authors:  John D Birkmeyer; Andrea E Siewers; Emily V A Finlayson; Therese A Stukel; F Lee Lucas; Ida Batista; H Gilbert Welch; David E Wennberg
Journal:  N Engl J Med       Date:  2002-04-11       Impact factor: 91.245

2.  Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population.

Authors:  Joan L Warren; Carrie N Klabunde; Deborah Schrag; Peter B Bach; Gerald F Riley
Journal:  Med Care       Date:  2002-08       Impact factor: 2.983

3.  Impact of hospital and surgeon volume on in-hospital mortality from radical cystectomy: data from the health care utilization project.

Authors:  Badrinath R Konety; Vibhu Dhawan; Veerasathpurush Allareddy; Sue A Joslyn
Journal:  J Urol       Date:  2005-05       Impact factor: 7.450

4.  Mortality after major surgery for urologic cancers in specialized urology hospitals: are they any better?

Authors:  Badrinath R Konety; Veerasathpurush Allareddy; Sanjukta Modak; Brian Smith
Journal:  J Clin Oncol       Date:  2006-05-01       Impact factor: 44.544

Review 5.  Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update.

Authors:  M Craig Hall; Sam S Chang; Guido Dalbagni; Raj Som Pruthi; John Derek Seigne; Eila Curlee Skinner; J Stuart Wolf; Paul F Schellhammer
Journal:  J Urol       Date:  2007-12       Impact factor: 7.450

6.  Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.

Authors:  Richard J Sylvester; Adrian P M van der Meijden; Willem Oosterlinck; J Alfred Witjes; Christian Bouffioux; Louis Denis; Donald W W Newling; Karlheinz Kurth
Journal:  Eur Urol       Date:  2006-01-17       Impact factor: 20.096

7.  The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years.

Authors:  S Holmäng; H Hedelin; C Anderström; S L Johansson
Journal:  J Urol       Date:  1995-06       Impact factor: 7.450

8.  Provider treatment intensity and outcomes for patients with early-stage bladder cancer.

Authors:  Brent K Hollenbeck; Zaojun Ye; Rodney L Dunn; James E Montie; John D Birkmeyer
Journal:  J Natl Cancer Inst       Date:  2009-04-07       Impact factor: 13.506

9.  Adherence to surveillance among patients with superficial bladder cancer.

Authors:  Deborah Schrag; Lillian J Hsieh; Farhang Rabbani; Peter B Bach; Harry Herr; Colin B Begg
Journal:  J Natl Cancer Inst       Date:  2003-04-16       Impact factor: 13.506

10.  Predictors of intravesical therapy for nonmuscle invasive bladder cancer: results from the surveillance, epidemiology and end results program 2003 patterns of care project.

Authors:  George J Huang; Ann S Hamilton; Mary Lo; John P Stein; David F Penson
Journal:  J Urol       Date:  2008-06-11       Impact factor: 7.450
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.